S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
NASDAQ:PRTA

Prothena (PRTA) Stock Price, News & Analysis

$22.24
-1.04 (-4.47%)
(As of 04/12/2024 ET)
Today's Range
$21.92
$23.33
50-Day Range
$22.24
$30.30
52-Week Range
$21.90
$79.65
Volume
526,230 shs
Average Volume
601,913 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.63

Prothena MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
213.1% Upside
$69.63 Price Target
Short Interest
Bearish
12.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of Prothena in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$170,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.89) to ($4.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.07 out of 5 stars

Medical Sector

367th out of 923 stocks

Pharmaceutical Preparations Industry

164th out of 430 stocks

PRTA stock logo

About Prothena Stock (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

PRTA Stock Price History

PRTA Stock News Headlines

Prothena (NASDAQ:PRTA) Sets New 52-Week Low at $21.91
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Prothena (NASDAQ:PRTA) Hits New 52-Week Low at $23.41
Demystifying Prothena Corp: Insights From 8 Analyst Reviews
Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Prothena Corporation plc (PRTA)
PRTA Mar 2024 105.000 call
Prothena Full Year 2023 Earnings: Beats Expectations
RBC Capital Reaffirms Their Hold Rating on Prothena (PRTA)
Decoding 6 Analyst Evaluations For Prothena Corp
Earnings Outlook For Prothena Corp
Navigating 5 Analyst Ratings For Prothena Corp
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/13/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTA
Employees
173
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$69.63
High Stock Price Target
$90.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+213.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-147,030,000.00
Net Margins
-160.91%
Pretax Margin
-175.64%

Debt

Sales & Book Value

Annual Sales
$91.37 million
Book Value
$10.46 per share

Miscellaneous

Free Float
38,571,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
0.21
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

PRTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price target for 2024?

9 Wall Street analysts have issued 1-year price objectives for Prothena's shares. Their PRTA share price targets range from $35.00 to $90.00. On average, they anticipate the company's share price to reach $69.63 in the next year. This suggests a possible upside of 213.1% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2024?

Prothena's stock was trading at $36.34 at the start of the year. Since then, PRTA shares have decreased by 38.8% and is now trading at $22.24.
View the best growth stocks for 2024 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) posted its earnings results on Thursday, February, 15th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.23) by $0.03. The biotechnology company earned $0.32 million during the quarter, compared to analysts' expectations of $2.15 million. Prothena had a negative net margin of 160.91% and a negative trailing twelve-month return on equity of 24.84%. The business's revenue for the quarter was down 99.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.12 EPS.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTA) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners